FY2026 Earnings Estimate for Harrow Issued By William Blair

Harrow, Inc. (NASDAQ:HROW) – Research analysts at William Blair lowered their FY2026 EPS estimates for shares of Harrow in a report released on Monday, July 14th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of $1.30 per share for the year, down from their previous forecast of $1.35. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million.

Several other analysts have also issued reports on HROW. HC Wainwright increased their price objective on Harrow from $57.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, May 12th. Cantor Fitzgerald began coverage on shares of Harrow in a research report on Friday. They set an “overweight” rating and a $76.00 target price for the company. B. Riley lowered their price objective on shares of Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Finally, BTIG Research began coverage on Harrow in a research note on Thursday, June 12th. They issued a “buy” rating and a $62.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harrow has a consensus rating of “Buy” and an average target price of $63.83.

Harrow Trading Up 2.0%

NASDAQ:HROW opened at $35.62 on Tuesday. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 2.01, a current ratio of 0.91 and a quick ratio of 0.85. The stock has a market cap of $1.31 billion, a PE ratio of -63.61 and a beta of 0.41. The stock’s 50-day moving average is $29.03 and its two-hundred day moving average is $28.74.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HROW. Woodmont Investment Counsel LLC boosted its stake in Harrow by 0.5% in the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company’s stock valued at $2,731,000 after acquiring an additional 445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Harrow by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company’s stock worth $582,000 after buying an additional 585 shares in the last quarter. Swiss National Bank grew its stake in shares of Harrow by 1.0% during the 4th quarter. Swiss National Bank now owns 59,300 shares of the company’s stock worth $1,990,000 after acquiring an additional 600 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Harrow in the 4th quarter valued at $25,000. Finally, MetLife Investment Management LLC increased its position in shares of Harrow by 5.7% in the fourth quarter. MetLife Investment Management LLC now owns 18,908 shares of the company’s stock valued at $634,000 after acquiring an additional 1,026 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.